Fig. 1From: Efficacy and safety of eflornithine (CPP-1X)/sulindac combination therapy versus each as monotherapy in patients with familial adenomatous polyposis (FAP): design and rationale of a randomized, double-blind, Phase III trialCPP-1/sulindac downregulates PAs via dual MoA: CPP-1X decreases PA synthesis by blocking ODC1, and sulindac increases PA catabolism and export by upregulating transport genes (PPARγ and SAT). MoA, mechanism of action; ODC1, ornithine decarboxylase; PA, polyamine; PPAR, peroxisome proliferator activated receptor; SAT, sialic acid transportBack to article page